Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
723 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.83 - $94.75
Previous Close$51.82
Volume1.01M
Average Volume (3M)1.36M
Market Cap
$6.21B
Enterprise Value$5.87B
Total Cash (Recent Filing)$452.40M
Total Debt (Recent Filing)$109.58M
Price to Earnings (P/E)-11.6
Beta0.52
Next Earnings
May 02, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding120,581,749
10 Day Avg. Volume1,155,740
30 Day Avg. Volume1,361,608
Standard Deviation0.21
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)32.10
Price to Sales (P/S)274.01
Price to Cash Flow (P/CF)-16.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.93
Enterprise Value/Gross Profit77.79
Enterprise Value/Ebitda-9.98
Forecast
1Y Price Target
$83.23Price Target Upside60.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market GrowthThe potential for Syfovre's market growth is supported by the trend of non-retina specialists starting to recognize and treat GA.
Product DemandNew accounts for Apellis are being added weekly in double digits, showing increasing demand for Syfovre among retinal specialists.
Product LeadershipSyfovre is seen as the best-in-class drug for GA, with management confident in its sustained leadership based on efficacy.
Bears Say
Financial PerformanceIncreased operational expenses coupled with decreased cash holdings indicate potential financial strain for the company.
Regulatory ChallengesThe EU re-examination of Syfovre's application is characterized as an 'uphill battle' with a low probability of success, potentially delaying or preventing market access in Europe.
Safety ConcernsConcerns over the risk of retinal vasculitis with Syfovre use have been noted by a key opinion leader, which could impact the drug's competitive edge and market perception.
---
Ownership Overview
15.03% Insiders
38.36% Mutual Funds
12.99% Other Institutional Investors
33.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $19.83 and its highest was $94.75 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 27, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.731 by $0.001.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.46.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 120,581,750 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.731. Following the earnings report the stock price went down -3.318%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Driehaus Capital Management LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 29M.
---
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.23 (60.61% Upside)
$83.23 (60.61% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.98%
12-Months-Change
Fundamentals
Return on Equity
-290.14%
Trailing 12-Months
Asset Growth
3.75%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q4 2024
0:00 / 0:00
---
APLS Stock 12 Months Forecast
Average Price Target
$83.23
▲(60.61% Upside)
Technical Analysis
Best Analysts Covering APLS
1 Year
1 Year Success Rate
19/29 ratings generated profit
1 Year Average Return
+20.83%
reiterated a buy rating 3 months ago
Copying Justin Kim's trades and holding each position for 1 Year would result in 65.52% of your transactions generating a profit, with an average return of +20.83% per trade.
---